Anshul Dhankher's questions to Rain Enhancement Technologies Holdco (RAIN) leadership • Q2 2023
Question
Anshul Dhankher of LifeSci Capital questioned whether Rain Oncology is targeting a specific 'sweet spot' in terms of development stage or deal structure for potential in-licensing opportunities.
Answer
CEO Avanish Vellanki responded that the company's primary focus is on clinical-stage assets to leverage the demonstrated expertise of its clinical organization, but he did not provide further specifics on deal structures or other criteria.